Chlamydomonas

NAPIGEN Completes $7.85 Million Funding Round to Advance Its Mitochondrial and Chloroplast Gene Editing Technology

Retrieved on: 
Tuesday, July 12, 2022
Technology, Biotechnology, Mitochondrion, Animal, Gene editing, CRISPR, Agriculture, CEO, Plant, RA, GLOBE, NIH, PeerJ, Chloroplast, Cell, Organelle, RNA, DNA, Vaccine, Chlamydomonas

WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.

Key Points: 
  • WILMINGTON, Del., July 12, 2022 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.
  • NAPIGEN will use the funding to apply its mitochondrial gene editing technology for hybrid seed production in wheat and rice.
  • More recently, NAPIGEN has applied its technology to gene editing of plant mitochondrial DNA in rice.
  • NAPIGEN also has received funding from the United Mitochondrial Disease Foundation and the NIH-SBIR program to apply its technology to gene editing of human mitochondrial DNA.

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

Retrieved on: 
Thursday, September 9, 2021
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, ARCUS, Precision BioSciences, Inc., iECURE, ARCUS, PRECISION BIOSCIENCES, INC., IECURE

In return, Precision has granted iECURE a license to use its PCSK9-directed ARCUS nuclease to insert genes into the well-characterized PCSK9 locus to develop treatments for four other pre-specified rare genetic diseases.

Key Points: 
  • In return, Precision has granted iECURE a license to use its PCSK9-directed ARCUS nuclease to insert genes into the well-characterized PCSK9 locus to develop treatments for four other pre-specified rare genetic diseases.
  • Precision will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments on sales of iECURE products developed with ARCUS.
  • We are excited to partner with Precision on this key pillar of our gene editing strategy, to advance this work for rare genetic diseases.
  • iECURE is an in vivo gene editing company striving to cure liver disorders with high unmet need.

New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing

Retrieved on: 
Tuesday, May 11, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chlamydomonadales, Biotechnology, Branches of biology, Molecular biology, Restriction enzymes, Life sciences, Chlamydomonas reinhardtii, Hydrogen production, Biology, I-CreI, Arcus, Chlamydomonas, ARCUS, Precision BioSciences, Inc., ARCUS, PRECISION BIOSCIENCES, INC.

ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.

Key Points: 
  • ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.
  • ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
  • Using ARCUS, the Company\xe2\x80\x99s pipeline consists of multiple \xe2\x80\x9coff-the-shelf\xe2\x80\x9d CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.
  • For more information about Precision BioSciences, please visit www.precisionbiosciences.com.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Top U.S Student Researchers in STEM and Humanities Win Scholarships at the National Junior Science and Humanities Symposium

Retrieved on: 
Thursday, May 2, 2019
Education, Primary, Secondary, University, Technology, Other Technology, Manufacturing, Engineering, Teens, Defense, Other Defense, Research, Other Science, Consumer, Science, Branches of biology, Biology, Organisms, Genome editing, Immune system, Biotechnology, Chlamydomonadales, Molecular biology, Varroa destructor, CRISPR, Thymol, Chlamydomonas

Research Title: Control of Varroa destructor Infestation with a Dual-function, Thymol-Emitting Honey Bee Hive Entranceway

Key Points: 
  • Research Title: Control of Varroa destructor Infestation with a Dual-function, Thymol-Emitting Honey Bee Hive Entranceway
    Research Title: Next Generation Intracellular Therapeutic Drug Delivery: A 3-Year Study of Gene Identification using CRISPR/Cas9 and Delivery of Inhibiting of Plasmids via Novel Exosomal Targeting in Acute Myeloid Leukemia
    Research Title: Whats in front of me?
  • Guiding Device for the Visually Impaired using Artificial Intelligence
    Research Title: Probing Stellar Remnant for Planetary Candidate; Analysis of K2 Target 251248385
    Genetic Modification of Chlamydomonas reinhardtii and Chlorella vulgaris as a Means of Inducing Multicellularity, and Lipid Production in High Throughput Strains for IncreasedEfficiency in Biofuel Production
    Research Title: Estimating CO2 Emissions from Large Cities using Low-Cost Sensors, Small Drone Technology and Bayesian Methods

Exploring Algae for Sustainable Nutrition on Innovations w/Ed Begley, Jr.

Retrieved on: 
Thursday, April 19, 2018
Chlamydomonadales, Hydrogen production, Botanical nomenclature, Chlamydomonas reinhardtii, Freshwater algae, Biology, Chlamydomonas, Algae, Tritón, Fiction

By the year 2050 it is estimated that the number of people who will be deficient for protein will drastically increase.

Key Points: 
  • By the year 2050 it is estimated that the number of people who will be deficient for protein will drastically increase.
  • This segment of Innovations will take a look at Triton Algae Innovations' (Triton) solution for the global protein shortage through its development of novel green algae products.
  • At Triton Algae Innovations, our solution is to unleash the true potential of nutritious micro-algae, which we refer to as the 'mother of all plants'," said Xun Wang, President and CEO of Triton Algea Innovations.
  • In this segment of Innovations, viewers will learn about the significant technology breakthroughs Triton has made on a strain of green algae, called Chlamydomonas reinhardtii.